{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:18:12Z","timestamp":1765887492230,"version":"build-2065373602"},"reference-count":101,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.msard.2012.11.003","type":"journal-article","created":{"date-parts":[[2013,1,9]],"date-time":"2013-01-09T22:47:19Z","timestamp":1357771639000},"page":"183-192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis"],"prefix":"10.1016","volume":"2","author":[{"given":"Kaarina","family":"Kowalec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Carleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Tremlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2012.11.003_bib1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib2","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1177\/009127000004001003","article-title":"Adverse drug reactions: a review of relevant factors","volume":"40","author":"Ajayi","year":"2000","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.msard.2012.11.003_bib3","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/clpt.2011.18","article-title":"Pharmacogenetic testing: time for clinical practice guidelines","volume":"89","author":"Amstutz","year":"2011","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib4","unstructured":"Bayer Health Care Pharmaceuticals Inc. Betaseron (Interferon Beta-1b) for SC Injection Drug Monograph; 2011. Retrieved January 10, 2012 from \u3008http:\/\/www.bayer.ca\/files\/BETASERON-PM-ENG-13JUL2011-133528.pdf\u3009"},{"key":"10.1016\/j.msard.2012.11.003_bib5","unstructured":"Biogen Idec. Avonex (Interferon-beta-1a) IM injection drug monograph; 2012a. Retrieved March 15, 2012 from \u3008http:\/\/www.avonex.com\/pdfs\/guides\/Avonex_Prescribing_Information.pdf\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib6","unstructured":"Biogen Idec. Tysabri (Natalizumab) Drug Monograph; 2012b. Retrieved May 20, 2012 from \u3008http:\/\/www.tysabrihcp.com\/pdfs\/I61061-13_PI.pdf\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib7","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.msard.2012.11.003_bib8","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1177\/1352458506070775","article-title":"MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis","volume":"12","author":"Butzkueven","year":"2006","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.msard.2012.11.003_bib9","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/pds.1772","article-title":"Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals","volume":"18","author":"Carleton","year":"2009","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.msard.2012.11.003_bib10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/1352458510388823","article-title":"High-dose frequency beta-interferons increase the risk of liver test abnormalities in multiple sclerosis: a longitudinal study","volume":"17","author":"Chan","year":"2011","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.msard.2012.11.003_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/653823","article-title":"Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier","volume":"202","author":"Chapagain","year":"2010","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.msard.2012.11.003_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.msard.2012.11.003_bib13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jneuroim.2009.01.012","article-title":"HLA class I and II alleles and response to treatment with interferon-beta in relapsing-remitting multiple sclerosis","volume":"210","author":"Comabella","year":"2009","journal-title":"Journal of Neuroimmunology"},{"year":"2005","series-title":"McAlpine's multiple sclerosis","author":"Compston","key":"10.1016\/j.msard.2012.11.003_bib14"},{"key":"10.1016\/j.msard.2012.11.003_bib15","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/brain\/awp164","article-title":"ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis","volume":"132","author":"Cotte","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.msard.2012.11.003_bib16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1055\/s-0029-1240009","article-title":"Genetic association studies in drug-induced liver injury","volume":"29","author":"Daly","year":"2009","journal-title":"Seminars in Liver Disease"},{"key":"10.1016\/j.msard.2012.11.003_bib17","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1001\/archderm.135.10.1277","article-title":"Localized lipoatrophy after glatiramer acetate injection in patients with remitting-relapsing multiple sclerosis","volume":"135","author":"Drago","year":"1999","journal-title":"Archives of Dermatology"},{"key":"10.1016\/j.msard.2012.11.003_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1017\/S0317167100002845","article-title":"Lipoatrophy in patients with multiple sclerosis on glatiramer acetate","volume":"31","author":"Edgar","year":"2004","journal-title":"The Canadian Journal of Neurological Sciences"},{"key":"10.1016\/j.msard.2012.11.003_bib19","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2012.11.003_bib20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/1352458508100967","article-title":"Therapy-related acute leukemia with Mitoxantrone: what is the risk and can we minimise it?","volume":"15","author":"Ellis","year":"2009","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.msard.2012.11.003_bib21","unstructured":"EMD Serono Inc. Novantrone (mitoxantrone for injection concentrate) drug monograph; 2011a. Retrieved March 20, 2012 from \u3008http:\/\/dailymed.nlm.nih.gov\/dailymed\/archives\/fdaDrugInfo.cfm?archiveid=56726\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib22","unstructured":"EMD Serono Inc. Rebif (Interferon-beta-1a) SC injection drug monograph; 2011b. Retrieved March 20, 2012 from \u3008http:\/\/www.emdserono.com\/cmg.emdserono_us\/en\/images\/rebif_tcm115_19765.pdf\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib23","unstructured":"European Database for Multiple Sclerosis. EDMUS; 2012. Retrieved May 30, 2012 from \u3008http:\/\/www.edmus.org\/index.html\u3009"},{"key":"10.1016\/j.msard.2012.11.003_bib24","unstructured":"European Medicines Agency. European Medicines Agency starts review of Gilenya (fingolimod). Retrieved January 20, 2012 from \u3008http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2012\/01\/news_detail_001425.jsp&mid=WC0b01ac058004d5c1&jsenabled=true\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib25","unstructured":"FDA. Drug Safety Communication: Mitoxantrone hydrochloride (marketed as Novantrone and generics) \u2013 Healthcare Professional Sheet text version;. 2008. Retrieved January 1, 2012 from \u3008http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm126445.htm\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib26","unstructured":"FDA. Drug Safety Communication: safety review of a reported death after the first dose of Multiple Sclerosis drug Gilenya (fingolimod); 2011. Retrieved January 1, 2012 from \u3008http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm284240.htm\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib27","unstructured":"FDA. Drug Safety Communication: New risk factor for progressive multifocal leukoencephalopathy (PML) associated with tysabri (natalizumab); 2012a. Retrieved January 20, 2012 from \u3008http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm288186.htm\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib28","unstructured":"FDA. FDA Drug Safety Communication: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod); 2012b. Retrieved May 14, 2012 from \u3008http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm303192.htm\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib29","unstructured":"FDA. Pharmacogenomic biomarkers in drug labels; 2012c. Retrieved March 1, 2012 from \u3008http:\/\/www.fda.gov\/Drugs\/ScienceResearch\/ResearchAreas\/Pharmacogenetics\/ucm083378.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=pharmacogenomic&utm_content=1\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib30","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2165\/00002018-200326110-00006","article-title":"Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance","volume":"26","author":"Francis","year":"2003","journal-title":"Drug Safety"},{"key":"10.1016\/j.msard.2012.11.003_bib31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/sj.clpt.6100087","article-title":"The pharmacogenetics research network: from SNP discovery to clinical drug response","volume":"81","author":"Giacomini","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib32","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/FPC.0b013e3281299169","article-title":"Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers","volume":"17","author":"Grossman","year":"2007","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.msard.2012.11.003_bib33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2217\/pgs.10.41","article-title":"Pharmacogenomics: the importance of accurate phenotypes","volume":"11","author":"Gurwitz","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.msard.2012.11.003_bib34","doi-asserted-by":"crossref","first-page":"e18506","DOI":"10.1371\/journal.pone.0018506","article-title":"Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders","volume":"6","author":"Haghikia","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2012.11.003_bib35","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1212\/WNL.0b013e318211c3c8","article-title":"Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes","volume":"76","author":"Hasan","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/1352458508100504","article-title":"Progressive lipoatrophy after cessation of glatiramer acetate injections: a case report","volume":"15","author":"Hashimoto","year":"2009","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.msard.2012.11.003_bib37","unstructured":"Health Canada. Gilenya (fingolimod): MS drug under Health Canada review in light of serious adverse events. Retrieved February 27, 2012 from \u3008http:\/\/www.hc-sc.gc.ca\/ahc-asc\/media\/advisories-avis\/_2012\/2012_28-eng.php\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1474-4422(05)70117-4","article-title":"Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis","volume":"4","author":"Hemmer","year":"2005","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib39","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1515\/dmdi.2011.009","article-title":"Ageing populations, complex diseases and their challenge to 21st century healthcare: the focus of the European Society for Pharmacogenomics and Theranostics","volume":"26","author":"Henney","year":"2011","journal-title":"Drug Metabolism and Drug Interactions"},{"key":"10.1016\/j.msard.2012.11.003_bib40","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s00415-009-0084-2","article-title":"Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy","volume":"256","author":"Johnson","year":"2009","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jneuroim.2011.01.009","article-title":"Recent insights into the mechanism of action of glatiramer acetate","volume":"235","author":"Kala","year":"2011","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.msard.2012.11.003_bib42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-beta in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2012.11.003_bib43","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/WNL.0b013e3181e0f7e6","article-title":"Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS","volume":"74","author":"Kingwell","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib44","unstructured":"Kowalec K, Ross CJD, Smith MA, Traboulsee A, Yoshida EM, Marrie R.A., et al. Genotype specific approaches to preventing interferon beta-induced liver injury in multiple sclerosis: work in progress 2011. In: Pharmacogenomics and personalized medicine conference, Hinxton UK, Wellcome Trust Scientific Conferences Abstract P11."},{"key":"10.1016\/j.msard.2012.11.003_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/1742-2094-9-93","article-title":"CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation","volume":"9","author":"Kowarik","year":"2012","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.msard.2012.11.003_bib46","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1600-6143.2005.00754.x","article-title":"The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I","volume":"5","author":"Koyrakh","year":"2005","journal-title":"American Journal of Transplantation"},{"key":"10.1016\/j.msard.2012.11.003_bib47","first-page":"CD004678","article-title":"Glatiramer acetate for multiple sclerosis","author":"La Mantia","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.msard.2012.11.003_bib48","first-page":"CD005181","article-title":"Interferon beta for secondary progressive multiple sclerosis","volume":"1","author":"La","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.msard.2012.11.003_bib49","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/sj.clpt.6100334","article-title":"The emerging role of pharmacogenomics in biologics","volume":"82","author":"Lacana","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib50","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"The Journal of the American Medical Association"},{"key":"10.1016\/j.msard.2012.11.003_bib51","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.2006.05.9048","article-title":"Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer","volume":"25","author":"Le","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.msard.2012.11.003_bib52","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/1352458511398371","article-title":"Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study","volume":"17","author":"Le","year":"2011","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.msard.2012.11.003_bib53","first-page":"88","article-title":"Cutaneous side-effects of immunomodulators in MS","volume":"17","author":"Lebrun","year":"2011","journal-title":"International MS Journal"},{"key":"10.1016\/j.msard.2012.11.003_bib54","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1042\/bj3550189","article-title":"Sphingosylphosphocholine is a naturally occurring lipid mediator in blood plasma: a possible role in regulating cardiac function via sphingolipid receptors","volume":"355","author":"Liliom","year":"2001","journal-title":"The Biochemical Journal"},{"key":"10.1016\/j.msard.2012.11.003_bib55","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2217\/pgs.10.111","article-title":"Pharmacogenomics and active surveillance for serious adverse drug reactions in children","volume":"11","author":"Loo","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.msard.2012.11.003_bib56","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib57","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s004150050568","article-title":"Localized lipoatrophy after prolonged treatment with copolymer 1","volume":"247","author":"Mancardi","year":"2000","journal-title":"Journal of Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib58","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1212\/WNL.0b013e3181dc1ae0","article-title":"Evidence report: the efficacy and safety of mitoxantrone (novantrone) in the treatment of multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology","volume":"74","author":"Marriott","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib59","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1212\/WNL.0b013e318238ee00","article-title":"Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone","volume":"77","author":"Martinelli","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib60","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jneuroim.2010.07.012","article-title":"Natalizumab treatment reduces endothelial activity in MS patients","volume":"227","author":"Millonig","year":"2010","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.msard.2012.11.003_bib61","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00002018-200427070-00004","article-title":"Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis","volume":"27","author":"Mittmann","year":"2004","journal-title":"Drug Safety"},{"key":"10.1016\/j.msard.2012.11.003_bib62","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1021\/jm00195a002","article-title":"Antitumor agents. 1. 1,4-Bis[(aminoalkyl)amino]-9,10-anthracenediones","volume":"22","author":"Murdock","year":"1979","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.msard.2012.11.003_bib63","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib64","unstructured":"Novartis Pharmaceuticals. Gilenya (Fingolimod capsules) drug monograph; 2012a. Retrieved May 20, 2012 from \u3008http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/gilenya.pdf\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib65","unstructured":"Novartis Pharmaceuticals. Novartis statement: Gilenya (Fingolimod) safety information update; 2012b. Retrieved May 30, 2012 from \u3008http:\/\/www.novartis.com\/downloads\/newsroom\/product-related-info-center\/statement-PML.pdf\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib66","article-title":"Masquerades of acquired demyelination in children: experiences of a national demyelinating disease program","author":"O'Mahony","year":"2012","journal-title":"Journal of Child Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib67","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1432-2277.2007.00623.x","article-title":"Fulminant hepatic failure and autoimmune disorders in patient with multiple sclerosis on interferon beta 1a: a fatal combination?","volume":"21","author":"Pietrosi","year":"2008","journal-title":"Transplant International"},{"key":"10.1016\/j.msard.2012.11.003_bib68","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/clpt.2010.245","article-title":"Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles","volume":"88","author":"Pirmohamed","year":"2010","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib69","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.drudis.2011.08.006","article-title":"Pharmacogenetics: past, present and future","volume":"16","author":"Pirmohamed","year":"2011","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.msard.2012.11.003_bib70","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/clpt.2011.30","article-title":"The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions","volume":"89","author":"Pirmohamed","year":"2011","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib71","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/clpt.2011.79","article-title":"Phenotype standardization for immune-mediated drug-induced skin injury","volume":"89","author":"Pirmohamed","year":"2011","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","article-title":"Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients","volume":"329","author":"Pirmohamed","year":"2004","journal-title":"British Medical Journal"},{"key":"10.1016\/j.msard.2012.11.003_bib73","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/FPC.0b013e328342a917","article-title":"Adipogenic gene variants in patients with HIV-associated lipodystrophy","volume":"21","author":"Pushpakom","year":"2011","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.msard.2012.11.003_bib74","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/clpt.2010.279","article-title":"CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network","volume":"89","author":"Relling","year":"2011","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib75","first-page":"CD002002","article-title":"Interferon in relapsing-remitting multiple sclerosis","author":"Rice","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.msard.2012.11.003_bib76","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.478","article-title":"Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy","volume":"41","author":"Ross","year":"2009","journal-title":"Nature Genetics"},{"key":"10.1016\/j.msard.2012.11.003_bib77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s12325-012-0005-0","article-title":"Contribution of endermology to improving indurations and panniculitis\/lipoatrophy at glatiramer acetate injection site","volume":"29","author":"Rubio Fernandez","year":"2012","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.msard.2012.11.003_bib78","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2217\/pgs.11.23","article-title":"Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect","volume":"12","author":"Sadee","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.msard.2012.11.003_bib79","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1097\/JNN.0b013e3181ee122b","article-title":"Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis","volume":"42","author":"Saunders","year":"2010","journal-title":"Journal of Neuroscience Nursing"},{"key":"10.1016\/j.msard.2012.11.003_bib80","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/GIM.0b013e318238b38c","article-title":"Personalizing medicine with clinical pharmacogenetics","volume":"13","author":"Scott","year":"2011","journal-title":"Genetics in Medicine"},{"issue":"1","key":"10.1016\/j.msard.2012.11.003_bib81","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1038\/nrg2443","article-title":"Universal health care, genomic medicine and Thailand: investing in today and tomorrow","volume":"9","author":"Seguin","year":"2008","journal-title":"Nature Reviews Genetics"},{"key":"10.1016\/j.msard.2012.11.003_bib82","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/clpt.2011.280","article-title":"Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers","volume":"91","author":"Sistonen","year":"2012","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib83","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/QAI.0b013e3181ecfeca","article-title":"A role for syndecan-1 and claudin-2 in microbial translocation during HIV-1 infection","volume":"55","author":"Smith","year":"2010","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.msard.2012.11.003_bib84","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1352458511435105","article-title":"Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab","volume":"18","author":"Sorensen","year":"2012","journal-title":"Multiple Sclerosis"},{"key":"10.1016\/j.msard.2012.11.003_bib85","unstructured":"Teva Pharmaceutical Industries Ltd. Copaxone (glatiramer acetate injection) drug monograph; 2011. Retrieved March 20, 2012 from \u3008http:\/\/tevacanadainnovation.com\/downloads\/Copaxone_Product_Monograph_EN.pdf\u3009"},{"key":"10.1016\/j.msard.2012.11.003_bib86","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1212\/WNL.62.4.628","article-title":"Liver injury associated with the beta-interferons for MS: a comparison between the three products","volume":"62","author":"Tremlett","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib87","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrgastro.2011.22","article-title":"Mechanisms of drug-induced liver injury: from bedside to bench","volume":"8","author":"Tujios","year":"2011","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.msard.2012.11.003_bib88","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1212\/WNL.0b013e31821043b5","article-title":"Primary varicella zoster infection associated with fingolimod treatment","volume":"76","author":"Uccelli","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib89","unstructured":"US General Accounting Office. FDA drug review: postapproval risks 1976\u201385; 1990. Retrieved February 1, 2012 from \u3008http:\/\/161.203.16.4\/d24t8\/141456.pdf\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib90","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.2217\/pgs.11.81","article-title":"Implementation of pharmacogenetics in clinical practice is challenging","volume":"12","author":"van Schie","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.msard.2012.11.003_bib91","doi-asserted-by":"crossref","first-page":"885","DOI":"10.2217\/pgs.09.33","article-title":"United Europeans for development of pharmacogenomics in multiple sclerosis network","volume":"10","author":"Vandenbroeck","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.msard.2012.11.003_bib92","unstructured":"Vass K. Real-life use of natalizumab: safety data from the Austrian Nation-wide Natalizumab Registry. ECTRIMS, Amsterdam NL, Congrex Switzerland Ltd.; 2011 Abstract P977."},{"key":"10.1016\/j.msard.2012.11.003_bib93","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","article-title":"Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Vermersch","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib94","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/clpt.2012.4","article-title":"A global agenda for a global challenge","volume":"91","author":"Vinhas de Souza","year":"2012","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.msard.2012.11.003_bib95","article-title":"Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children","author":"Visscher","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.msard.2012.11.003_bib96","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.22605","article-title":"Fingolimod treatment for multiple sclerosis patients what do we do with varicella?","volume":"70","author":"Winkelmann","year":"2011","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-060309-164311","article-title":"Role of postmarketing surveillance in contemporary medicine","volume":"62","author":"Woodcock","year":"2011","journal-title":"Annual Review of Medicine"},{"key":"10.1016\/j.msard.2012.11.003_bib98","unstructured":"World Health Organization-Uppsala Monitoring Centre. The use of the WHO-UMC system for standardized case causality assessment; 2012. Retrieved February 1, 2012 from \u3008http:\/\/who-umc.org\/Graphics\/24734.pdf\u3009."},{"key":"10.1016\/j.msard.2012.11.003_bib99","unstructured":"World Health Organization. Atlas: multiple sclerosis resources in the world. 2011. Retrieved October 28, 2011 from \u3008http:\/\/www.who.int\/mental_health\/neurology\/Atlas_MS_WEB.pdf\u3009"},{"key":"10.1016\/j.msard.2012.11.003_bib100","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/nrneurol.2009.158","article-title":"Pediatric multiple sclerosis","volume":"5","author":"Yeh","year":"2009","journal-title":"Nature Reviews Neurology"},{"key":"10.1016\/j.msard.2012.11.003_bib101","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.56.10.1416","article-title":"Fulminant liver failure during interferon beta treatment of multiple sclerosis","volume":"56","author":"Yoshida","year":"2001","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034812001320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034812001320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:35:41Z","timestamp":1761899741000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034812001320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S2211034812001320"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2012.11.003","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2012.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}